Impact of Immunotherapy in Metastatic Kidney Cancer in Germany after Introduction of New Target Therapy - Results of a Telephone Survey of the German Society of Immuno- and Targeted Therapy (DGFIT).

TY - JOUR

T1 - Impact of Immunotherapy in Metastatic Kidney Cancer in Germany after Introduction of New Target Therapy - Results of a Telephone Survey of the German Society of Immuno- and Targeted Therapy (DGFIT).

AU - Siebels, M

AU - Staehler, M

AU - Hegele, A

AU - Varga, Z

AU - Oberneder, R

AU - Doehn, C

AU - Heinzer, Hans

PY - 2009

Y1 - 2009

N2 - INTRODUCTION: Until recently, the standard therapy for metastatic renal cell carcinoma (mRCC) in Germany consisted of interleukin-2 (IL-2), inter-feron-alfa (IFN) as single agents or in combina-tion, with or without chemotherapy. Since 2005, new drugs (target drugs) in the therapy for mRCC are avaible. The aim of this study was to analyse the current therapy standard in Germany. METHODS: By representative telephone interviews (GFK-Nürnberg by order of DGFIT) the following colleagues were contacted A: urologists in private practice (n = 40), B: oncologists in private practice (n = 40), C: hospital urologists (n = 35) and D: hospital oncologists (n = 35). Screening criteria were 1) responsibility for therapy in mRCC; 2) therapy of at least 10 patients with mRCC per year. RESULTS: Patiens / year: A: n = 19, B: n = 17, C: n = 43, D: n = 21. 98 % of patients with mRCC were treat-ed: A: the most frequent therapy was sunitinib (43 %, 42 %, 33 % as first-, second-, third-line), B: the most frequent therapy was sunitinib (45 % as first-line, 37 % as second-line), the most frequent third-line therapy was sorafenib (35 %); C: the most frequent therapy were sorafenib and sunitinib (first-line 26 % vs. 27 %, second-line 46 % vs. 42 %), in third-line therapy additionally temsirolimus 24 %; D: primary sorafenib and sunitinib (first-line 33 % vs. 40 %, second-line 46 % vs. 42 %), in third-line therapy additionally temsirolimus 23 %. Immunotherapy (IL-2, IFN with or without chemotherapy) in mRCC plays in Germany for the second- and third-line therapy in A-D no -major role (less than 10 %). Otherwise, for first-line therapy immunotherapy has some relevance: A: 25 %, B: 37 %, C: 33 %, D: 16 %. The most important criteria for therapy decision making in A-D were: efficacy, toxicity, drug approval status. CONCLUSIONS: Most patients with mRCC in Ger-many were seen by hospital urologists. Sunitinib (in first-line) and sorafenib (in second-line) are currently the most frequent prescribed drugs in mRCC. Temsirolimus is used mostly for third-line therapy (followed by sunitinib / sorafenib). Treatment of mRCC in Germany is increasingly being performed by oncologists.

AB - INTRODUCTION: Until recently, the standard therapy for metastatic renal cell carcinoma (mRCC) in Germany consisted of interleukin-2 (IL-2), inter-feron-alfa (IFN) as single agents or in combina-tion, with or without chemotherapy. Since 2005, new drugs (target drugs) in the therapy for mRCC are avaible. The aim of this study was to analyse the current therapy standard in Germany. METHODS: By representative telephone interviews (GFK-Nürnberg by order of DGFIT) the following colleagues were contacted A: urologists in private practice (n = 40), B: oncologists in private practice (n = 40), C: hospital urologists (n = 35) and D: hospital oncologists (n = 35). Screening criteria were 1) responsibility for therapy in mRCC; 2) therapy of at least 10 patients with mRCC per year. RESULTS: Patiens / year: A: n = 19, B: n = 17, C: n = 43, D: n = 21. 98 % of patients with mRCC were treat-ed: A: the most frequent therapy was sunitinib (43 %, 42 %, 33 % as first-, second-, third-line), B: the most frequent therapy was sunitinib (45 % as first-line, 37 % as second-line), the most frequent third-line therapy was sorafenib (35 %); C: the most frequent therapy were sorafenib and sunitinib (first-line 26 % vs. 27 %, second-line 46 % vs. 42 %), in third-line therapy additionally temsirolimus 24 %; D: primary sorafenib and sunitinib (first-line 33 % vs. 40 %, second-line 46 % vs. 42 %), in third-line therapy additionally temsirolimus 23 %. Immunotherapy (IL-2, IFN with or without chemotherapy) in mRCC plays in Germany for the second- and third-line therapy in A-D no -major role (less than 10 %). Otherwise, for first-line therapy immunotherapy has some relevance: A: 25 %, B: 37 %, C: 33 %, D: 16 %. The most important criteria for therapy decision making in A-D were: efficacy, toxicity, drug approval status. CONCLUSIONS: Most patients with mRCC in Ger-many were seen by hospital urologists. Sunitinib (in first-line) and sorafenib (in second-line) are currently the most frequent prescribed drugs in mRCC. Temsirolimus is used mostly for third-line therapy (followed by sunitinib / sorafenib). Treatment of mRCC in Germany is increasingly being performed by oncologists.

M3 - SCORING: Zeitschriftenaufsatz

JO - AKTUEL UROL

JF - AKTUEL UROL

SN - 0001-7868

ER -